原発、転移メラノーマにおけるドライバー変異の比較研究：腫瘍内、腫瘍間不均一性について by Kaji, Tatsuya
1 
 
1 
 
Original article JDS 
Comparative study on driver mutations in primary and metastatic 
melanomas at a single Japanese institute: A clue for intra- and 
inter-tumor heterogeneity 
Tatsuya Kaji a,f, Osamu Yamasaki a,f, Minoru Takata a,b, Masaki Otsuka a,c , Toshihisa Hamada a, 
Shin Morizane a, Kenji Asagoe d, Hiroyuki Yanai e,f, Yoji Hirai a, Hiroshi Umemura a, Keiji 
Iwatsuki a, f* 
 
a: Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan 
b: Okada Orthopedics and Dermatology Clinic, 39-1 Kamigori, Hyogo, 678-1225, Japan 
c: Division of Dermatology, Shizuoka Cancer Center, 1007 Nagaizumi-cho, Shizuoka, 411-8777, 
Japan 
d: Department of Dermatology, National Hospital Organization Okayama Medical Center, 1711-1 
Tamasu, Kita-ku, Okayama, 701-1154, Japan 
e: Department of Diagnostic Pathology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, 
Okayama, 700-8558, Japan 
f: Melanoma Center, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, 
Japan 
 
Running head: Driver mutations in melanoma 
Abstract; 299 words, Text; 2935 words, Tables; two, Figure; one, References; 30 
Supplementary data; one figure (Fig. S1) 
Funding: described in Acknowledgments 
2 
 
2 
 
* Corresponding author: Keiji Iwatsuki, M.D., Ph.D, Department of Dermatology, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. 2-5-1 Shikata-cho, Kita-ku, 
Okayama, 700-8558, Japan 
Tel.: +81 86 235 7282; Fax: +81 86 235 7283. E-mail: keijiiwa@cc.okayama-u.ac.jp 
3 
 
3 
 
ABSTRACT 
Background: Searching for driver mutations in melanoma is critical to understanding melanoma 
genesis, progression and response to therapy. 
Objectives: We aimed to investigate the frequency and pattern of driver mutations in Japanese 
primary and metastatic melanomas including cases of unknown primary origin, in relation to their 
clinicopathologic manifestations. 
Methods: Seventy-seven samples from 60 patients with melanoma were screened for 70 driver 
mutations of 20 oncogenes by Sequenom MelaCarta MassARRAY, and the results for primary and 
metastatic melanomas were compared. 
Results: Of 77 tissue samples, BRAF V600E was detected in 21 samples (27%), CDK4 R24C in 7, 
EPHB6 G404S in 6, BRAF V600K in 2, NEK10 E379K in 2, and CDK4 R24H, NRAS Q61K, NRAS 
Q61R, KRAS G12A, KIT L576P, KIT V559A, ERBB4 E452K, and PDGFRA E996K in one sample 
each. No driver mutations related to the MAPK cascade including RAS and BRAF were detected in 
the chronically sun-damaged (CSD) group of melanoma. Dual or triple driver mutations were found 
in four of 40 (10%) samples from the primary melanomas, and three of 37 (8%) of the metastatic 
melanomas. Fourteen of 26 (54%) samples of non-CSD melanoma, and 3 of 6 (50%) melanomas of 
unknown primary origin had the BRAF V600E mutation. Mutations in membrane-bound receptors 
including KIT, ERBB4 and EPHB6 were detected in 8 of 77 (10%) samples. Of 17 pairs of primary 
and metastatic melanomas from the same patient, the primary mutation pattern was changed to a 
novel one in three cases, and only one of the plural mutations in the primary melanoma was found in 
the metastatic lesions in two cases.   
Conclusions: BRAF V600E is a predominant mutation in non-CSD melanoma and melanomas of 
unknown primary origin. Mutational heterogeneity may exist in the primary melanoma (intra-tumor 
heterogeneity), and between the primary and metastatic lesions (inter-tumor heterogeneity).  
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1. Introduction 
Recent genome sequencing has revealed that cutaneous melanomas possess a greater mutation 
load than other solid tumors [1-3]. The mutations in cutaneous melanomas are characterized by a 
distinct pattern reflecting the frequent C > T mutations caused by misrepair of ultraviolet 
(UV)-induced covalent bonds between adjacent pyrimidines [1]. Among the mutations, it is 
important to distinguish the driver mutations that are directly related to the oncogenesis of melanoma 
from the passenger mutations without oncogenic significance. For instance, a driver mutation 
frequently observed in melanoma, BRAF V600E, does not appear attributable to direct UV-induced 
damage [2]. Actually, BRAF V600E mutation is frequently detected in non-chronically sun damaged 
(non-CSD) melanoma, and often found among younger patients [3].  From the clinical view point, 
the search for driver mutations offers therapeutic insights for patients with melanoma. The presence 
of the BRAF V600E mutation predict the efficacy of BRAF inhibitors such as vemurafenib and 
dabrafenib [4, 5]. While, both driver and passenger mutations of melanomas may provide 
neoantigens targeted by cytotoxic T lymphocytes (CTLs).  In addition to CD8+ lymphocyte 
infiltration and the presence of mismatch repair deficiency, the mutation load correlates with the 
response of melanomas to immunotherapy[6-8]. 
  Mutation patterns of melanomas are known to be related to the clinical phenotypes of chronically 
sun-damaged (CSD), non-CSD, acral, and mucosal melanomas in Caucasians [9,10], and the 
frequencies of melanoma phenotypes differ according to race [11]. The first aim of the present study 
was to investigate the frequency and pattern of driver mutations in Japanese patients with melanoma, 
and to address their relation to these various phenotypes. Although BRAF, NRAS and KIT mutations 
were examined in a large series of Japanese melanoma patients [12], we have employed more 
comprehensive method to analyze 70 point mutations in 20 putative melanoma oncogens[13]. 
One type of mutation known to activate the mitogen-activated protein kinase (MAPK) signaling 
pathway, mainly BRAF mutations, is frequently detected in early lesions of melanoma and even in 
benign melanocytic nevi [14]. Melanoma cells may gain additional driver mutations during 
progression; i.e., TERT promotor mutations in in situ lesions, biallelic inactivation of CDKN2A in 
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early invasive primary tumors , and PTEN and/or TP53 mutations in advanced primary melanomas. 
Apart from this genomic evolution model, there has been a concept of mutational heterogeneity of 
carcinogenesis, in which the primary tumor is thought to be composed of several neoplastic 
subclones with different mutation patterns [15, 16]. The second aim of the present study was to 
prove the possibility that plural driver mutations exist in primary tumors, and that the initial mutation 
pattern can be altered in the metastatic lesion. Here we report that BRAF V600E is the predominant 
mutation in Japanese non-CSD melanoma patients, and that both intra- and inter-tumor mutational 
heterogeneities exist in primary and metastatic melanomas. 
 
2. Material and methods 
2.1 Patients and tissue samples 
The present study was performed with the ethical board committee approval of Okayama 
University Hospital (No. 2139, 2014), and the patients’ written informed consent were obtained. 
Sixty patients with melanoma were enrolled in the present study. According to the anatomical sites 
and clinical phenotypes of the primary lesions, the melanomas were classified into four groups: CSD 
melanoma, 5 cases; non-CSD melanoma, 26 cases; acral melanoma, 21 cases; unknown primary 
origin, 6 cases; and mucosal melanoma, 2 cases (Table 1). Seventy-seven samples were obtained 
from 60 patients with melanoma by surgical removal for therapeutic or diagnostic purposes. Of these 
60 patients, primary cutaneous lesions were examined in 23 patients, the metastatic lesions in 20 
patients (lymph node; 13 patients, lung; 4, and skin; 3), and both the primary and metastatic lesions 
in 17 patients.  
 
2.2 Detection of driver mutations 
Sections from formalin-fixed, paraffin-embedded tissue samples were assayed for driver 
mutations. Before extraction of DNA, we confirmed the percentages of melanoma cells included as 
more than 10% of the cellular components. Somatic mutations were screened using the Sequenom 
MassARRAY system (MelaCarta Panel v1.0 , Agena Bioscience, San Diego ), which is able to 
6 
 
6 
 
detect 70 driver mutations in 20 oncogenes including BRAF, KIT, and NRAS [13]. In brief, 20 ng of 
genomic DNA extracted from the tissue sections was used for polymerase chain reaction (PCR) 
amplification. A single base-pair extension reaction was performed using iPLEX Pro chemistry 
(Agena Bioscience, San Diego), and resin-treated samples were spotted onto SpectroCHIP II arrays 
(Agena Bioscience, San Diego). Mutant alleles were then distinguished via mass spectrometry 
(MassARRAY System, Agena Bioscience, San Diego ). Mutations were detected by a minimum 5% 
threshold of the mutant allele peak, and allele peaks below the 5% threshold were designated as 
“mutation not detected” (MND). With the present array system, at least one mutation can be found in 
approximately 70% of all melanomas [17].  
 
2.3 Comparison with the patients’ clinicopathologic findings and mutation profiles 
The profile of driver mutations was compared with the patients’ clinical data and the melanoma 
subtypes. In order to address the genetic evolution of melanomas, the identities of somatic mutations 
in primary and metastatic melanomas of the same patient were compared. 
 
2.4 Immunophenotyping of melanoma cells 
Phenotypes of melanoma cells were examined by immunohistochemistry using specific 
antibodies to HMB45 (clone HMB45, DAKO, Glostrup), tyrosinase (clone T311, Leica Biosystems, 
Nussloch) and MART-1 (clone M2-7C10, COVANCE, Dedham) on an automated 
immunohistochemistry staining instrument, BenchMark® XT (Roche, Basel ). 
 
2.5 Statistical analysis 
We analyzed the results using Fisher’s exact test (JMP® 11, SAS Institute Inc, Cary, NC). 
Differences were considered significant when P < 0.05. 
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3. Results  
3.1. The profile of driver mutations  
Of 77 tissue samples from 60 patients, including both primary and metastatic melanomas, driver 
mutations were detected in 38 samples: BRAF V600E was detected in 21 samples (27%), CDK4 
R24C in 7, EPHB6 G404S in 6, BRAF V600K in 2, NEK10 E379K in 2, and CDK4 R24H, NRAS 
Q61K, NRAS Q61R, KRAS G12A, KIT L576P, KIT V559A, ERBB4 E452K, and PDGFRA E996K in 
one sample each (Table 1). BRAF mutations were observed more frequently in the younger patient 
groups (<49 years; 7/12, >50-69 years; 8/23, >70 years; 5/25) (Fig 1a). Among the different stages 
of melanomas, BRAF mutations were detected in 0%, 17%, 53% and 40% in the stage I, II, III and 
IV melanoma, respectively (Fig 1b). 
Dual or triple mutations were found in four of 40 (10%) samples from the primary lesion (cases 
8, 12, 35, 36 in Table 1), and three of 37 (8%) from the metastatic lesions (cases 35, 58, 59 in Table 
1). No driver mutations, designated as “mutation not detected” (MND), were found in 28 of 60 
(47%) patients.  
 
3.2. Driver mutations in melanoma subtypes 
Of 60 patients, 52 patients with primary cutaneous melanomas were classified into three 
subtypes: non-CSD; 26 patients, CSD; five patients, and acral; 21 patients. Of the remaining patients, 
six were classified as unknown primary origin, and two as mucosal melanoma.  
Among the melanoma subtypes, BRAF mutations were mainly detected in patients with 
non-CSD melanoma and in the unknown-primary-origin group: 14 of 26 (54%), and three of six 
(50%), respectively (Fig 1c). The frequency of BRAF mutations in the non-CSD group was 
significantly higher than that in the CSD group (non-CSD; 14/26, CSD; 0/5, P = 0.0482). There was 
no clear difference in the frequency of BRAF mutations between the primary and metastatic 
melanomas (primary; 10/40, metastasis; 12/37, P = 0.6144) (Fig 1d). 
Mutations in molecules related to the MAPK signaling pathway, including NRAS, KRAS and 
BRAF, were detected in 26 of 77 (34%) samples, although no such mutations were detected in the 
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CSD melanoma in our series. Mutations in membrane-bound receptors including KIT, ERBB4 and 
EPHB6 were detected in seven of 60 (12%) patients: two (8%) of 26 patients with non-CSD 
melanoma, four of 21 (19%) patients with acral melanoma, and one of six (17%) patients with 
unknown origin melanoma. There was no clear difference in frequency or melanoma subtype 
between patients with mutations in the MAPK signaling pathway and membrane receptors.  
 
3.3. Mutational heterogeneity in the primary melanoma 
   Of 40 patients with primary melanoma examined, plural driver mutations were observed in the 
same primary melanoma from four patients (10%) (Table 1): namely, NRAS Q61R + EPHB6 G404S 
mutations (case 8; 85 y.o., non-CSD, stage IIIC), BRAF V600E + CDK4 R24C (case 35; 71 y.o., 
ALM, stage IIIB), EPHB6 G404S + KRAS G12A + NEK10 E379K (case 36; 66 y.o., ALM, stage 
IIIA), and CDK4 R24H + EPHB6 G404S (case 12; 55 y.o., non-CSD, stage IIA). In the metastatic 
lesions, three(9%) of 33 samples revealed two or three driver mutations: namely, BRAF V600E + 
BRAF V600K in case 35, BRAF V600E + CDK4 R24C in case 58, and EPHB6 G404S + PDGFRA 
E996K + ERBB4 E452K in case 59. Therefore, mutational heterogeneity can exist in both primary 
and metastatic melanomas. There was no duplicate mutation involving both RAS and RAF genes, 
both of which are gene members of the MAPK signaling pathway. 
 
3.4. Comparison of the driver mutations in the primary and metastatic lesions in the same patient. 
In 17 patients (Table 2), both the primary and metastatic lesions were examined for driver 
mutations. Six of those (Cases 8, 15, 16, 22, 35, 36 in Table 2) revealed at least one driver mutation 
in both types of lesion. One patient (case 15) possessed the same BRAF V600E mutation in both the 
primary and metastatic lesions. In three cases, the driver mutation(s) in the primary lesions were 
changed to other mutation(s) in the metastatic lesions: BRAF V600E + CDK4 R24C was changed to 
BRAF V600E + BRAF V600K in case 35; and BRAF V600E was changed to CDK4 R24C in two 
patients (case 16 and 22). Furthermore, BRAF V600E mutation found in the primary tumor was no 
longer detected in the metastatic lesions in four patients (cases 5, 6, 34, and 41). In contrast, BRAF 
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V600E mutation present in the metastases was not detected in the primary tumors in two patients 
(cases 7 and 26). In two patients, one of the plural mutations in the primary melanoma survived in 
the metastatic lesions (cases 8, and 36). These results indicate inter-tumor heterogeneity in the 
mutations of melanomas. No certain therapeutic regimen was noted to account for the alteration of 
driver mutations in the group of patients with inter-tumor heterogeneity. 
 
3.5 Immunophenotyping in the primary melanoma and the metastatic lesion with different driver 
mutations 
No clear difference was observed in morphological findings or the expression of HMB-45, MART-1 
or tyrosinase in cases with different driver mutations in the primary and metastatic lesions (cases 8, 
16, 35 and 36). (Fig. S1) 
 
4. Discussion 
Consistent with the results in previous study [12], the present study revealed that BRAF 
mutations such as BRAF V600E and BRAF V600K were predominantly observed in the non-CSD 
melanoma (54%), especially in the younger patient group (Fig 1a). No BRAF or RAS mutation was 
detected in the tissue samples from the CSD melanoma. Previous studies have shown that, in general, 
the non-CSD melanomas occur earlier in life and have lower mutation burdens, frequently bearing 
the BRAF V600E mutation [14]. In contrast, the CSD melanomas usually occur on the head and neck 
areas of the elderly, and are characterized by the presence of higher mutation burdens including 
NRAS, NF1, KIT and BRAF non-V600E. Our study also found that the BRAF V600E mutation is 
predominant in non-CSD melanomas; mutations other than BRAF V600E were detected in the CSD 
melanomas. 
  Three of 6 (50%) melanoma samples from the unknown primary origin revealed the presence of 
the BRAF V600E mutation in our series. Therefore, as reported previously in Caucasian patients [18], 
the mutation pattern of this group is similar to that of the non-CSD melanoma group, suggesting that 
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a significant proportion of these cases arise from regressed or unrecognized primary cutaneous 
melanomas.  
It is noteworthy that EPHB6 G404S mutation, which was not highlighted in the recent report of 
The Cancer Genome Atlas database (TCGA) [19], is the third common mutation (five of 60 patients) 
detected in our series. Since three of five patients with EPHB6 G404S mutation were acral 
melanomas, the discrepancy between the TCGA and the present study might be explained by the 
higher proportion of acral melanoma in our series (35%). Interestingly, Jones et al [20] have recently 
reported significant difference of EPHB6 G404S mutation rates in the North Island versus South 
Island of New Zealand (7.8% vs 0%), and speculated that the difference depends primarily on 
environmental risk factors, namely, differences in intermittent sun exposure or type of UV radiation. 
Although mutations in EPHB6 have been observed recurrently in other cancers such as non-small 
cell lung cancer, the functional consequence of the G404S mutation is currently unknown [21]. 
Etiology and significance of this mutation need to be investigated in future studies. Melanomas 
harboring NF1 mutations are classified into one of the representative genomic subgroups [19]. 
Unfortunately, however, our array system used for the present study is not designed for detection of 
the NF1 mutations. 
With the present array system, no driver mutation (the MND group), designated as the wild type 
(WT) elsewhere, was found in 28 of 60 (47%) patients, the frequency of which was rather high as 
compared with the previous data using the same method [17]. In order to explain this, we should 
consider the lack of sensitivity of our array system or the scanty amount of tumor cell-derived DNA. 
As we expected, the percentages of the MND were high in the stages I and II diseases, as compared 
with those in the stages III and IV diseases (Fig 1b). We believe that the high frequency of the MND 
group in our series might be related to the small tumor burden in the tissue sections obtained from 
the patients with the stages I and II, and irrelevant to the mutational evolution of melanoma cells in 
progression of the disease. 
It has been reported that BRAF mutations can be detectable in the early melanoma, and even in 
melanocytic nevi [14]. Our study, however, indicates that BRAF mutations were absent or detected 
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in a low frequency in the stages I and II melanoma (Fig 1b), while such mutations were more 
frequently detected in the younger group of patients (Fig 1a), and in the certain subtypes such as 
non-CSD melanomas and melanomas of unknown primary origin (Fig 1c). Since the average age of 
patients with non-CSD melanoma (58.1 years) was younger than that of other patient groups 
including CSD, acral and mucosal melanomas (69.4 years), the clinical subtype of non-CSD 
melanoma might influence the association of BRAF mutations more strongly than the patient’s age.  
   It is intriguing to note that two or more driver mutations were detected in four of the 40 (10%) 
primary melanomas. Mutational heterogeneity in the primary tumor was previously observed in 
melanoma by Sensi et al [22], and Eriksson et al [23]. Furthermore, our comparative study of driver 
mutations between the primary and metastatic lesions provides evidence that only one of several 
driver mutations in the primary lesions was selected in the process of metastasis in two patients 
(NRAS Q61R in case 8 and EPHB6 G404S in case 36). These results are consistent with the concept 
of intra- and inter-tumor heterogeneity observed previously [24-27], and clearly indicate that there 
exist distinct neoplastic subclones harboring different driver mutations within the primary melanoma 
tumor, some of which may give rise to metastases [15,16].  
Since BRAF and NRAS mutations are found both in melanoma and melanocytic nevus, it is 
postulated that these mutations are a founder event in melanomagenesis [28]. However, actual 
carcinogenic pathways from melanocyte to melanoma are thought to be more complex [9]. We also 
observed in paired samples of primary tumor and metastasis from the same patient that in six out of 
17 (35%) patients with BRAF V600E mutation found in primary tumor was either not detected 
(cases 5,6,34 and 41) or was changed to CDK4 R24C mutation (cases 16 and 22). This indicates that 
minor subclones without having BRAF V600E mutation were present in the primary tumor and 
evolved into metastasis. On the other hand, in cases 7 and 26, BRAF V600E mutation was detected 
only in metastasis, suggesting that acquisition of this mutation occurred later after the divergence of 
metastatic subclone. Thus, our observations strongly suggest that in a substantial number of patients, 
BRAF V600E mutation is not a founder mutation in melanoma development, and highlight the 
complex intra- and inter-tumor heterogeneity of melanoma. Alternatively, we should consider the 
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possibility that the low amount of melanoma cell-derived DNA in the tested samples gave a negative 
result for BRAF V600E mutations. 
Intra-tumoral heterogeneity is a matter of concern for the treatment of melanoma, because the 
remnant of subclones resistant to the initial therapy can lead to disease relapse and metastasis. 
Actually, BRAF inhibitors elicit rapid antitumor responses in the majority of melanoma patients with 
the BRAF V600E mutation, but drug resistance occurs within several months [4]. Recent 
observations on cell-mediated immune responses against melanomas indicate that a high clonal 
neoantigen burden is associated with dense infiltration of effector T cells, and longer 
progression-free survival [29, 30]. Although we still do not know whether the therapeutic regimens 
such as radiation and cytotoxic chemotherapy are a driving force to induce selection of a certain 
melanoma clone, we should pay attention to the selection of subclones with metastatic potential, and 
to the genetic evolutionary processes involved in the introduction of additional mutations. As far as 
we studied, it seems difficult to know the genomic heterogeneity by routine morphological findings 
or immunophenotyping (Fig. S1). 
In conclusion, BRAF V600E is a predominant mutation in non-CSD melanoma. Mutational 
heterogeneity may be present within the primary melanomas, and also occur between the primary 
and metastatic melanomas. 
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Table 1.  Clinical backgrounds of 60 patients and the driver mutations 
Case no. Age Sex Site Type Stage
tumor
thickness(m
m)
Primary tumor
Mutant
allele
freque
Metastasis
Mutan
t allele
freque
1 53 M Abdomen non-CSD III B 2.3 NE BRAF  V600E 0.15
2 68 F Arm non-CSD IV 5 NE BRAF  V600K 0.53
3 32 M Thigh non-CSD IV 2.8 MND MND
4 70 F Chest non-CSD II A 1.8 BRAF  V600E 0.13 NE
5 62 F Lower leg non-CSD III C 3.4 BRAF  V600E 0.14 MND
6 55 F Thigh non-CSD III B 3.3 BRAF  V600E 0.12 MND
7 34 F Thigh non-CSD III C 1.2 MND BRAF  V600E 0.46
8 85 F Arm non-CSD III C 12
NRAS  Q61R
EPHB6
0.32
0.16
NRAS  Q61R 0.28
9 35 F Thigh non-CSD II B 4.2 BRAF  V600E 0.14 NE
10 91 F Chest non-CSD IV 5.9 NE MND
11 79 F Arm non-CSD III B 4.2 NE MND
12 55 F Shoulder non-CSD II A 2.2
CDK4  R24H
EPHB6
0.3
0.19
NE
13 59 M Abdomen non-CSD IV 5 NE MND
14 61 F Arm non-CSD III B 2 NE BRAF  V600E 0.2
15 55 F Arm non-CSD IV 1.9 BRAF  V600E 0.39 BRAF  V600E 0.36
16 64 M Back non-CSD III B 4.2 BRAF  V600E 0.15 CDK4  R24C 0.06
17 59 F Back non-CSD II A 3.5 MND NE
18 45 M Back non-CSD IV 4.5 NE BRAF  V600E 0.08
19 71 M Abdomen non-CSD III A 3 NE MND
20 59 M Arm non-CSD I B 1.5 MND NE
21 62 F Arm non-CSD I A in situ CDK4  R24C 0.13 NE
22 32 F Back non-CSD III B 7.2 BRAF  V600E 0.17 CDK4  R24C 0.08
23 22 F pople non-CSD IV unknown NE BRAF  V600E 0.49
24 55 M Thigh non-CSD I B 1.3 MND NE
25 71 M Arm non-CSD I A 0.9 CDK4  R24C 0.06 NE
26 77 Ｆ pople non-CSD III B 1.3 MND BRAF  V600E 0.38
27 53 F Lip CSD I B 1.9 NEK10  E379K 0.38 NE
28 59 F Neck CSD IV 2.7 NE MND
29 51 F Ear CSD II B 4.3 MND NE
30 92 Ｆ Cheek CSD II C 4.6 MND NE
31 43 M Head CSD I B 1.6 MND NE
32 77 M Foot acral II B 3.6 MND NE
33 82 M fifth toe acral IV 8 MND MND
34 72 M Sole acral IV 15 BRAF  V600E 0.14 MND
35 71 M Third toe acral III B 3.8
BRAF  V600E
CDK4  R24C
0.11
0.13
BRAF  V600E
BRAF  V600K
0.17
0.12
36 66 M Sole acral III A 0.7
EPHB6
G404S
KRAS  G12A
0.25
0.14
0.14
EPHB6  G404S 0.12
37 56 M First toe acral III B 5.5 MND MND
38 78 F Sole acral IV 5 NE NRAS  Q61K 0.56
39 66 M Sole acral II A 2.2 EPHB6  G404S 0.26 NE
40 75 F Sole acral II B 2.9 MND NE
41 85 F Sole acral III C 6.1 BRAF  V600E 0.12 MND
42 80 F Sole acral III A 0.9 MND MND
43 84 F Heel acral II B 2.2 KIT  L576P 0.16 NE
44 39 F First finger acral II C 5.5 MND NE
45 42 Ｆ First finger acral I A 0.2 MND NE
46 74 Ｆ Sole acral I A 0.5 MND NE
47 93 M Sole acral III B 4.9 MND MND
48 69 M Sole acral I A 0.5 MND NE
49 80 F Heel acral III B 6 CDK4  R24C 0.05 NE
50 94 Ｆ Heel acral II C 10.3 MND NE
51 59 M Heel acral III C 11 KIT  V559A 0.8 NE
52 50 M First finger acral IV 0.5 NE MND
53 84 F Conjunctiva mucosal IV NE MND
54 70 Ｆ Vulva mucosal IV NE MND
55 61 M Unknown unknown IV NE BRAF  V600E 0.24
56 48 F Unknown unknown IV NE MND
57 48 M Unknown unknown IV NE BRAF  V600E 0.1
58 45 F Unknown unknown IV NE
BRAF  V600E
CDK4  R24C
0.12
0.16
59 76 M Unknown unknown IV NE
EPHB6
G404S
PDGFRA
E996K
0.33
0.08
0.12
60 82 M Unknown unknown IV NE MND  
CSD, chronically sun-damaged melanoma; MND, mutation not detected; NE, not examined. 
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Table2. Comparison of driver mutations in the primary and metastatic lesions 
Case no. Primary tumor Metastasis site of metastasis Treatment
8
NRAS  Q61R
EPHB6  G404S
NRAS  Q61R lymph node excision, LND, IFNβ
15 BRAF  V600E BRAF  V600E
lymph node, lung,
bone, ovary,
peritoneum
excision, LND
vemurafenib, nivolumab
16 BRAF  V600E CDK4  R24C lymph node excision, LND
22 BRAF  V600E CDK4  R24C lymph node excision, LND, IFNβ
35
BRAF  V600E
CDK4  R24C
BRAF  V600E
BRAF  V600K
lymph node amputation, LND
36
EPHB6  G404S
KRAS  G12A
NEK10  E379K
EPHB6  G404S lymph node
excision, LND,
D-IFNβ 6 course, IFNβ
5 BRAF  V600E MND lymph node excision, LND, IFNβ
6 BRAF  V600E MND lymph node excision, LND, IFNβ
34 BRAF  V600E MND lymph node, brain
excision, LND,
DAC-Tam-IFN 3 course, IFNβ
41 BRAF  V600E MND lymph node excision, LN resection, vemurafenib
7 MND BRAF  V600E lymph node
excision, LND,
DAC-Tam-IFN 4 course, IFNβ
26 MND BRAF  V600E lymph node excision, LND, IFNβ
3 MND MND lymph node, lung, skin excision, LND, D-IFNβ 6 course
33 MND MND lymph node, bone amputation, LND, ipilimumab
37 MND MND lymph node amputation, LND
42 MND MND lymph node
excision, LND,
D-IFNβ 5 course, IFNβ
47 MND MND lymph node excision, LN resection
 
MND, mutation not detected; LND, lymph node dissection; IFNβ, interferonβ local injection; D- 
IFNβ, DTIC intravenous injection + interferonβ local injection; DAC-Tam-IFN, 
DTIC,ACNU,CDDP intravenous injection + TAM oral treatment + interferonβ local injection. 
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Legends for figures 
Fig 1. Percentages of driver mutations detected 
a                                        b 
 
c                                        d 
 
 
BRAF mutations are detected in the younger patient group (< 49 years) more frequently than in the 
elderly group (a). BRAF mutation is absent in patients with the stage I disease, and less frequently 
observed in the stage II. In the stages III and IV, the relative frequencies of BRAF mutations are 
increased (the stages III and IV include 6 primary (Pr.) and 5 metastatic (Me.) lesions, and 2 Pr. and 
7 Me. lesions, respectively) (b). BRAF mutations are frequently associated with non-CSD 
melanomas and melanomas of unknown primary origin. Note that the average age of patients with 
non-CSD melanoma (58.1 years) is younger than that of other patient group (69.4 years) (c). No 
clear difference is observed in frequency of BRAF mutations among the primary, metastatic and 
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unknown origin melanomas. (d). Eight cases harbor a combination of mutations as follows: ＃
NRAS Q61R+EPHB6 G404S, 〇CDK4 R24C+EPHB6 G404S, ▽BRAF V600E+CDK4 
R24C, □BRAF V600E+CDK4 R24C, ☆BRAF V600E+BRAF V600K+CDK4 R24C, ◇
EPHB6 G404S+KRAS G12A+NEK10 E379K, △BRAF V600E+CDK4 R24C, ＊EPHB6 
G404S+PDGFRA E996K+ERBB4 E452K.   
 
 
Legends for supplementary data (Fig S1) 
 
No clear difference is observed in the morphologic findings or the expression of HMB-45, MART-1 
or tyrosinase in cases with different driver mutations in the primary and metastatic lesions (case 16). 
